Evidence map›Paper›PMID 38662716›Full record

ArticlePloS one2024

miR-21, miR-221, miR-29 and miR-34 are distinguishable molecular features of a metabolically unhealthy phenotype in young adults.

Alejandro Méndez-Mancilla, Eneida Turiján-Espinoza, Mariela Vega-Cárdenas, Gloria Estela Hernández-Hernández, Edith Elena Uresti-Rivera, Juan M Vargas-Morales, Diana P Portales-Pérez

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alejandro Méndez-MancillaLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Eneida Turiján-EspinozaLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Mariela Vega-CárdenasTranslational and Molecular Medicine Department, Research Center for Health Sciences and Biomedicine (CICSaB), Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Gloria Estela Hernández-HernándezLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Edith Elena Uresti-RiveraLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Juan M Vargas-MoralesLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.
Diana P Portales-PérezLaboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Sciences, Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico.ORCID 0000-0001-8063-7869
Autonomous University of San Luis Potosí · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Discrepancies between the measurement of body mass index (BMI) and metabolic health status have been described for the onset of metabolic diseases. Studying novel biomarkers, some of which are associated with metabolic syndrome, can help us to understand the differences between metabolic health (MetH) and BMI. A group of 1469 young adults with pre-specified anthropometric and blood biochemical parameters were selected. Of these, 80 subjects were included in the downstream analysis that considered their BMI and MetH parameters for selection as follows: norm weight metabolically healthy (MHNW) or metabolically unhealthy (MUNW); overweight/obese metabolically healthy (MHOW) or metabolically unhealthy (MUOW). Our results showed for the first time the differences when the MetH status and the BMI are considered as global MetH statures. First, all the evaluated miRNAs presented a higher expression in the metabolically unhealthy group than the metabolically healthy group. The higher levels of leptin, IL-1b, IL-8, IL-17A, miR-221, miR-21, and miR-29 are directly associated with metabolic unhealthy and OW/OB phenotypes (MUOW group). In contrast, high levels of miR34 were detected only in the MUNW group. We found differences in the SIRT1-PGC1α pathway with increased levels of SIRT1+ cells and diminished mRNA levels of PGCa in the metabolically unhealthy compared to metabolically healthy subjects. Our results demonstrate that even when metabolic diseases are not apparent in young adult populations, MetH and BMI have a distinguishable phenotype print that signals the potential to develop major metabolic diseases.

Indexed as

Body Mass IndexMicroRNAsBiomarkersFemaleHumansLeptinMaleMetabolic SyndromeObesityPhenotypeSirtuin 1Young AdultBiomarkersLeptinMicroRNAsMIR221, humanMIRN21 microRNA, humanMIRN29a microRNA, humanMIRN34 microRNA, humanSIRT1 protein, humanSirtuin 1

Identifiers

PMID38662716
PMCPMC11045123
OpenAlexW4395448710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.